如果你可以”完全覺得Malone係 inventor”,點解我覺得佢唔係inventor有問題?你覺得佢30年前既一篇論文有足夠既 credit成為” inventor”呢樣嘢本來就好主觀, the latter paper said in its conclusion, this technology “may provide alternative approaches to vaccine development.” 你覺得係直升機飛起,我覺得只係一個 idea一張草圖。甚至佢本人同你最開頭都講佢唔係疫苗既 inventor只係疫苗 platform既 inventor,你點解可以咁肯定佢因為三十年前既研究過下 mouse cells就有能力對今日既 human use既疫苗效用性/安全性有 say呢?
你既 summary解釋唔到疫苗變種前降低感染入院死亡急降數字,最多係話有負作用,不完美。相對於封城,我唔介意一年一針直至有 better solution。well…你可以継續 put words in my mouth打稻草人話我搬龍門,標籤我左膠etc,但你有做功課,I give you that,我真懶(蠢),唔回啦
, the latter paper said in its conclusion, this technology “may provide alternative approaches to vaccine development.” 你覺得係直升機飛起,我覺得只係一個 idea一張草圖。
我最佩服你呢D layman, 連佢論文都未識睇 (老實講, 我都未識睇), 但依家你又有面講"佢係一個idea 佢係一個草圖", 作為一個layman, 你無知識都勁撚有勇氣呀, 唔撚知醜果種勇氣
:^(
甚至佢本人同你最開頭都講佢唔係疫苗既 inventor只係疫苗 platform既 inventor,你點解可以咁肯定佢因為三十年前既研究過下 mouse cells就有能力對今日既 human use既疫苗效用性/安全性有 say呢?
你行到只係識玩詭辯, 想搵我唔知的地方去搵破綻, 你無知識同時連知性上的誠實勇氣都無.
不過我對玩詭辯果D人, 都係咁回架啦
你點解可以咁肯定佢因為三十年前既研究過下 mouse cells就無能力對今日既 human use既疫苗效用性/安全性有 say呢?
話佢唔掂果個係一個連醫學都唔識FC撚, 佢只能剪報左媒貼出黎做FC, 但你信佢
VS
而佢本人出埋論文講哂內容, 但你睇唔明/無睇/我只係一個layman呀, 但你唔信佢
1. Ogata, A.F. et al. (2021) Circulating SARS-CoV-2 Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients. Clin. Infect. Dis (preprint)
2. Amanat, F. et al. (2021) SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD and S2. Cell (preprint)
3. Wisnewski, A.V. et al. (2021) Human IgG and IgA responses to COVID-19 mRNA vaccines. PLoS One 16:e0249499
4. Qu, J. et al. (2020) Profile of Immunoglobulin G and IgM Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. 71:2255-2258
5. Le Bert, N. et al. (2020) SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature 584:457-462
6. Grifoni, A. et al. (2020) Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell 181:1489-1501.e15
7. Gallais, F. et al. (2021) Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion. Emerg. Infect. Dis. 27 (preprint)
8. Nielsen, S.S. et al. (2021) SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity. EBioMedicine 68:103410
9. Magro, C.M. et al. (2020) Docked severe acute respiratory syndrome coronavirus 2 proteins within the cutaneous and subcutaneous microvasculature and their role in the pathogenesis of severe coronavirus disease 2019. Hum. Pathol. 106:106-116
10. Magro, C.M. et al. (2021) Severe COVID-19: A multifaceted viral vasculopathy syndrome. Annals of diagnostic pathology 50:151645
11. Tseng, C. et al. (2012) Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One 7:e35421
12. McCullough, P.A. et al. (2021) Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection. Am. J. Med. 134:16-22
13. Johnson, L. (2021) Official Vaccine Injury and Fatality Data: EU, UK and US.
用條友第一個”significance”做例子
Fact A係s1 protein will circulate after vaccination
B係”This explains the many clotting-related adverse events—stroke, heart attack, venous thrombosis—that are being reported after vaccination.”